NEW YORK (GenomeWeb News) – The Multiple Myeloma Research Foundation today announced that US Oncology Research has joined a network of partners to study the genetic and molecular basis of multiple myeloma.
Seventeen clinical sites affiliated with US Oncology Research will participate in the MMRF-sponsored study called CoMMpass (Relating Clinical Outcomes in MM to Personal Assessment of Genetic Profile), which will follow 1,000 newly diagnosed multiple myeloma patients over a five-year period. Sequential tissue sampling during the study, launched last year, will help explain how a patient's molecular profile may influence clinical progression and response to treatment, MMRF said, adding that the ultimate goal is to facilitate clinical trials and personalized treatment strategies.
The 17 US Oncology Research sites that now will participate in the study are Arizona Oncology; Broome Oncology in New York; Cancer Care Centers of South Texas; Cancer Care Centers of South Texas-HOAST; Cancer Care Northwest in Washington; Cancer Center of Kansas; Comprehensive Cancer Centers of Nevada; Illinois Cancer Specialists; Compass Oncology in Washington; Ocala Oncology in Florida; Rockwood Clinic in Washington; Rocky Mountain Cancer Centers in Colorado; Texas Oncology-Fort Worth; Texas Oncology-Garland; Texas Oncology-Plano East; Texas Oncology-Tyler; and Texas Oncology-Waco.
They join 22 other centers that are currently enrolling patients in CoMMpass, MMRF said. In April, MMRF announced Translational Genomics Research Institute, Spectrum Health, and the Van Andel Research Institute as participants in the study.
US Oncology Research is a community-based research network specializing in Phase 1 to IV oncology clinical trials.